Jun 5th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

On May 22, Biogen Inc. and Human Immunology Biosciences (HI-Bio) announced an acquisition agreement. Biogen will acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.

Jun 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The European Commission has approved Bristol Myers Squibb's Opdivo® (nivolumab) combined with cisplatin and gemcitabine for first-line therapy in adults with unresectable or metastatic urothelial carcinoma.

5.27-6.2 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Jazz Pharmaceuticals plc revealed that the U.S. Food and Drug Administration (FDA) has accepted and given Priority Review status to the Biologics License Application (BLA) for zanidatamab.

Full-Life Technologies Receives FDA IND Clearance for 225Ac-FL-020 to Treat Metastatic Castration-Resistant Prostate Cancer.

VBI Vaccines Releases New Tumor Response Results from Ongoing Phase 2b Study of VBI-1901 in Patients with Recurrent Glioblastoma.

CDR-Life Inc. has started enrolling participants for the Phase 1 clinical trial of CDR404, their leading candidate being developed as a targeted immunotherapy for the treatment of solid tumors.

LIB Therapeutics Shares Positive Phase 3 Lerodalcibep Results at 92nd European Atherosclerosis Society Congress.

Atara Biotherapeutics Presents Early Research on ATA3219, a CAR T Therapy Targeting CD19 for B-Cell Autoimmune Diseases, at ISCT 2024.

The partnership involves the commercialization and licensing of BAT2506, a biosimilar of Simponi® (golimumab).